Skip to main content

Table 1 Patient baseline demographics

From: A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors

Patient characteristic huKS-IL2 dosing cohort, mg/m2 Total (N = 27)
0.5 1.0 2.0 3.0 4.0
(n = 3) (n = 4) (n = 7) (n = 6) (n = 7)
Age, years       
 Median 47 55 59 57 63 58
 Range 47–58 46–69 46–68 49–61 53–67 46–69
Sex, n (%)       
 Men 0 1 (25) 4 (57) 1 (17) 4 (57) 10 (37)
 Women 3 (100) 3 (75) 3 (43) 5 (83) 3 (43) 17 (63)
Tumor type, n (%)       
  Ovarian carcinoma 3 (100) 2 (50) 3 (43) 4 (67) 3 (43) 15 (56)
  Lung carcinoma 0 0 0 2 (33) 2 (29) 4 (15)
  Colon 0 2 (50) 1 (14) 0 0 3 (11)
  Prostate 0 0 1 (14) 0 1 (14) 2 (7)
  Othera 0 0 2 (29) 0 1 (14) 3 (11)
Tumor stage, n (%)       
  I 0 0 1 (14) 0 1 (14) 2 (7)
 II 0 1 (25) 0 0 0 1 (4)
 III 3 (100) 3 (75) 1 (14) 4 (67) 2 (29) 13 (48)
 IV 0 0 5 (71) 2 (33) 4 (57) 11 (41)
Prior chemotherapy, n (%) 3 (100) 4 (100) 6 (86) 6 (86) 6 (86) 25 (93)
Prior radiotherapy, n (%) 0 2 (50) 3 (43) 3 (43) 3 (43) 10 (37)
  1. a Other includes 1 patient each of melanoma, acinic cell carcinoma, and adenocarcinoma of unknown origin.
  2. huKS-IL2, humanized KS-interleukin-2.